Zealand Pharma AS (OCSE:ZEAL) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OCSE:ZEAL Zealand Pharma AS OCSE:ZEAL
68 GF Score
Price kr293.30
! 3 Warning Signs
View Full Analysis

What is Zealand Pharma AS Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

OCSE:ZEAL vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, Zealand Pharma AS's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zealand Pharma AS Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's Short Interest distribution charts can be found below:

* The bar in red indicates where Zealand Pharma AS's Short Interest falls into.


OCSE:ZEAL
68GF Score
Zealand Pharma AS OCSE:ZEAL
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zealand Pharma AS Business Description

Address Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
68GF Score

Get the complete analysis for OCSE:ZEAL

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr293.30
Price